From Earlier: Barrington Research Reiterates Spectranetics Outperform, $13 PT

Barrington Research reiterated its Spectranetics

Outperform rating and $13 price target in a research report published today. In the report, Barrington Research stated, "We believe there is a significant growth opportunity for SPNC's vascular intervention business as it is expected to gain more indications and more awareness over the next couple of years. SPNC has recently launched a Peripheral Artery Disease ("PAD") market awareness program. PAD has a huge addressable market of 15 million people, and only less than 15% are diagnosed or treated. We believe this program will help the company achieve its double-digit growth as time goes on." Shares of Spectranetics closed today at $10.46, down 0.29% from Monday's market close.